Status:
UNKNOWN
Evaluation of Serum Gasdermin D Level As a Potential Biomarker of Disease Activity in Vitiligo Patients
Lead Sponsor:
Assiut University
Conditions:
Serum Gasdermin D in Vitiligo
Eligibility:
All Genders
10-75 years
Brief Summary
Assessment the serum level of Gasdermin D level in vitiligo patients. Correlate its level with disease activity scores using Vitiligo Area Severity Index (VASI) and Vitiligo Disease Activity (VIDA) sc...
Detailed Description
Vitiligo, a common depigmenting skin disorder, has an estimated prevalence of 0.5-2% of the population worldwide. The disease is characterized by the selective loss of melanocytes which results in typ...
Eligibility Criteria
Inclusion
- All clinically diagnosed cases of vitiligo (segmental and non-segmental).
Exclusion
- patients with inflammatory diseases.
- patients with autoimmne diseases.
- patients with neurodegenerative diseases.
- patients with HIV or COVID19 infection or any other type of infections.
- patients with systemic diseases as liver diseases or having tumors.
- patients who received systemic treatment in the last 3 months or topical treatment 1 month prior to the study.
Key Trial Info
Start Date :
November 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT06584643
Start Date
November 1 2024
End Date
December 1 2025
Last Update
September 5 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.